OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
ROCKVILLE, Md., March 07, 2018 -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following March investor conferences:
Barclays Global Healthcare Conference
Date: Wednesday, March 14, 2018
Location: Loews Miami Beach Hotel, Miami, FL
Fireside chat: Wednesday, March 14, 2018 at 3:20 p.m. ET
Morgan Stanley Healthcare Corporate Access Day
Date: Tuesday, March 20, 2018
Location: Boston Harbor Hotel at Rowes Wharf, Boston, MA
A live webcast of the Barclays fireside chat can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
[email protected]
Media
Adam Pawluk, 202-591-4063
[email protected]
